RMC No. 30-2022: Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)

Files
Download this file

Summary

RMC No. 30-2022 publishes the full text of a Food and Drug Administration letter endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act).

Key points

  1. Letter published. The letter comes from OIC-Director General Oscar G. Gutierrez, Jr. of the Food and Drug Administration.
  2. Medicines to add. The letter names medicines for cancer, diabetes, hypertension, high-cholesterol, mental illness and COVID-19 for inclusion in the List.
  3. Delisting and correction. It also names a medicine for cancer for delisting and a medicine for COVID-19 for correction in the List.

Summary by Tax Resources PH. It is not a substitute for the full text of the issuance or professional advice.

Copies of BIR issuances are hosted here for reference. For the official version, check bir.gov.ph. Summaries by Tax Resources PH are not a substitute for the full text or professional advice.